Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
respiratory syncytial virus
Pharma
Moderna plots launch of its next potential mRNA vaccine approval
Moderna expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, teeing up a potential U.S. launch this fall.
Fraiser Kansteiner
May 2, 2024 11:08am
GSK's Arexvy dominates RSV market ahead of new competition
May 1, 2024 11:20am
Sanofi is going all in on Dupixent's next potential nod in COPD
Apr 25, 2024 12:37pm
Pfizer plots new RSV filing with positive Abrysvo data in adults
Apr 9, 2024 6:45am
In year 2, Pfizer's RSV vax Abrysvo retains most of its efficacy
Feb 29, 2024 8:02am
Amid supply constraints, Sanofi has big ambitions for Beyfortus
Feb 1, 2024 9:59am